trial

Improving Cognition in Schizophrenia Using tDCS

NCTId NCT02539797
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 37 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2016-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
37 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Single
Start
2014-10
Primary completion
2016-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
TDCS

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Investigators

1
Yuri Rassovsky, PhDPrincipal Investigator

Sites

1 total
Los Angeles, United States

Facts & assertions

4 sourced
Enrollment
37
Phase
NA
Primary Completion Date
2016-10
Status
COMPLETED
relationships
The graph out of here
drug
TDCS
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Yuri Rassovsky, PhD
person